Novartis AG Company Profile (NYSE:NVS)

Analyst Ratings

Consensus Ratings for Novartis AG (NYSE:NVS) (?)
Ratings Breakdown: 2 Sell Rating(s), 9 Hold Rating(s), 3 Buy Rating(s)
Consensus Rating:Hold (Score: 2.07)
Consensus Price Target: $93.00 (11.70% upside)

Analysts' Ratings History for Novartis AG (NYSE:NVS)
Show:
DateFirmActionRatingPrice TargetActions
7/19/2016JPMorgan Chase & Co.Reiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/12/2016Bank of America Corp.Reiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/24/2016Citigroup Inc.Reiterated RatingNeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/13/2016Jefferies GroupReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/2/2016Leerink SwannReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/22/2016Barclays PLCUpgradeUnderweight -> Equal WeightView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/14/2016Credit Suisse Group AGReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/12/2016Morgan StanleyDowngradeEqual Weight -> UnderweightView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/5/2016ArgusInitiated CoverageHold -> HoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/28/2016BNP ParibasDowngradeOutperform -> NeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/7/2016Goldman Sachs Group Inc.Boost Price TargetNeutral$89.00 -> $92.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/23/2015VontobelDowngradeHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/28/2015Sanford C. BernsteinLower Price TargetOutperform$102.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/28/2015Main First Bank AGDowngradeUnderperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/7/2015Oddo SecuritiesInitiated CoverageBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/25/2015HSBCInitiated CoverageBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/22/2015Bryan, Garnier & CoUpgradeNeutral -> BuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/4/2015NatixisUpgradeNeutral -> BuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/5/2015Cowen and CompanyUpgradeMarket Perform -> Outperform$95.00 -> $105.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/13/2014Kepler Capital MarketsUpgradeHold -> BuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/31/2014 forward)

Earnings

Earnings History for Novartis AG (NYSE:NVS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
7/19/2016Q216$1.18$1.23$12.33 billion$12.47 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/21/2016Q116$1.18$1.17$11.90 billion$11.60 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
1/27/2016Q415$1.18$1.14$12.64 billion$12.52 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/27/2015Q315$1.31$1.27$12.66 billion$12.30 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/21/2015Q215$1.20$1.27$12.45 billion$12.70 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/23/2015Q115$1.10$1.33$12.90 million$11.94 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
1/27/2015Q314$1.21$1.21$14.68 billion$14.63 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/28/2014Q3$1.31$1.33$14.51 billion$14.70 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/17/2014Q214$1.36$1.36$14.83 billion$14.64 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/24/2014$1.27$1.31$14.25 billion$14.02 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
1/29/2014Q413$1.27$1.20$15.16 billion$15.08 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/22/2013Q313$1.31$1.26$14.28 billion$14.34 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/17/2013Q213$1.29$1.30$14.39 billion$14.50 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/24/2013Q113$1.28$1.32$14.02 million$14.02 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
1/23/2013Q412$1.19$1.27$14.42 billion$14.80 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/25/2012$1.34$1.34ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/19/2012$1.33$1.38ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/24/2012$1.30$1.27ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
1/25/2012$1.26$1.23ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/25/2011$1.45$1.45ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/19/2011$1.46$1.48ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/19/2011$1.30$1.41ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
1/27/2011$1.25$1.14ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Novartis AG (NYSE:NVS)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163$1.17$1.18$1.17
Q2 20163$1.12$1.21$1.17
Q3 20161$1.19$1.19$1.19
Q4 20162$1.13$1.24$1.19
(Data provided by Zacks Investment Research)

Dividends

Current Dividend Information for Novartis AG (NYSE:NVS)
Annual Dividend:$2.30
Dividend Yield:2.76%
Payout Ratio:82.14% (Based on Trailing 12 Months of Earnings)
48.32% (Based on Current Year Consensus EPS Estimate)
44.83% (Based on Next Year Consensus EPS Estimate)
Dividend Growth:2.40% (3 Year Average)

Dividend History for Novartis AG (NYSE:NVS)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable DateShare
2/1/2016Annual$2.342/24/20162/26/20162/26/2016Tweet This Announcement  Share This Announcement on StockTwits
2/4/2014annual$2.723.48%2/27/20143/3/20143/11/2014Tweet This Announcement  Share This Announcement on StockTwits
2/11/2013annual$2.533.71%2/26/20132/28/20134/5/2013Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading History for Novartis AG (NYSE:NVS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
5/11/2016Institutes For Biomed NovartisMajor ShareholderBuy277,777$18.00$4,999,986.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/17/2016Bioventures Ltd NovartisMajor ShareholderBuy375,000$8.00$3,000,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/22/2014Bioventures Ltd NovartisMajor ShareholderBuy325,000$15.00$4,875,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Novartis AG (NYSE:NVS)
DateHeadline
07/29/16 12:44 PMETF’s with exposure to Novartis AG : July 29, 2016 -
07/28/16 08:45 AMTwo Buzzers within Analysts Radar: Medtronic plc (NYSE:MDT) , Novartis AG (NYSE:NVS) - Street Updates
07/28/16 08:45 AMStock under consideration: Novartis AG (NYSE:NVS) - News Oracle
07/28/16 07:36 AMAstraZeneca a bid target again? CEO says someone may spot value -
07/27/16 05:54 PMAfter $1 billion buyout, team quickly builds another cancer-fighting company
07/27/16 10:04 AMAnalyst Recommendations for Roche: Buy, Hold, or Sell? -
07/26/16 09:15 AMNovartis AG :NVS-US: Earnings Analysis: Q2, 2016 By the Numbers : July 26, 2016 -
07/22/16 05:25 PMA Look at the Stock Strength for Novartis AG (NYSE:NVS) - Engelwood Daily
07/22/16 05:25 PMAre Analysts Still Saying "Buy" this Stock: Novartis AG (NYSE:NVS) - TGP
07/22/16 05:25 PMAttention Grasping Stock With Upward Momentum: Novartis AG (NYSE:NVS) - TGP
07/22/16 03:11 PMEli Lilly, J&J, Novo Battle Diabetes -- And Each Other -
07/21/16 05:50 PMAnalyst's Overview of Two Stocks: CytRx Corporation (NASDAQ:CYTR) , Novartis AG (NYSE:NVS) - Street Updates
07/21/16 08:26 AMAnalysts Observable Stocks: CVS Health Corporation (NYSE:CVS) , Novartis AG (NYSE:NVS) - Street Updates
07/21/16 08:26 AMFort Washington Investment Advisors INC Increased Novartis Ag (NYSE:NVS) by $9.77 Million as Shares Declined - Consumer Eagle
07/21/16 08:26 AMNovartis: On Road To Recovery? - Seeking Alpha
07/21/16 08:26 AMAnalyst Consideration on this Stock: Novartis AG (NYSE:NVS) - News Oracle
07/21/16 08:26 AMNovartis AG (NVS) Joseph Jimenez on Q2 2016 Results - Earnings Call Transcript - Seeking Alpha
07/21/16 01:20 AMRoche Beats First-Half Forecasts as Cancer Drug Sales Rise -
07/20/16 06:18 PMNext Weeks Broker Price Targets For Novartis AG (NYSE:NVS)
07/20/16 09:15 AMNovartis (NVS) Tops Q2 Earnings & Sales, Expenses to Grow -
07/20/16 08:30 AMNovartis (NVS) Beats Earnings & Sales in Q2
07/20/16 08:30 AMNovartis AG (NVS) Joseph Jimenez on Q2 2016 Results - Earnings Call Transcript
07/19/16 05:41 PMNew Heart Failure Drug Marketing Costs to Alleviate Novartis’ 2016 Profit
07/19/16 05:41 PMNovartis AG (NVS) Scheduled to Post Earnings on Tuesday
07/19/16 04:30 PMAmgen Finally Scores a Win in Its Big Copycat Drug Battle With Novartis -
07/19/16 03:47 PMNovartis Shares Slip Tuesday on Falling Profit -
07/19/16 07:53 AMNovartis Q2 Profit Down 3%; Lowers FY Core Operating Income Outlook
07/19/16 07:53 AMNovartis Q2 Profit Hurt By Gleevec Generic Impact; Warns On Annual Profit
07/19/16 07:42 AMU.S. FDA knocks back Novartis copy of Amgen's drug Neulasta - [Reuters] - U.S. regulators have declined to approve Novartis' so-called biosimilar copy of Amgen's Neulasta drug that fights infections in cancer patients, the Swiss drugmaker said on Tuesday. Vasant Narasimhan, head of development at Novartis Pharmaceuticals, said the Food and Drug Administration (FDA) had issued a complete response letter for the product at the end of June, without giving further details. The FDA typically issues such letters when more information is needed to allow approval.
07/18/16 05:40 PMAnalyst Target and Average Rating Watch: Novartis AG (NYSE:NVS) - Press Telegraph
07/18/16 05:40 PMAnalysts Pounding the Table on Shares of Novartis AG (NYSE:NVS) - TGP
07/18/16 05:40 PMWhy Earnings Season Could Be Great for Novartis AG (NVS) - Nasdaq
07/18/16 10:59 AMWhy Earnings Season Could Be Great for Novartis AG (NVS)
07/17/16 04:58 PMNext Weeks Broker Price Targets For Novartis AG (NYSE:NVS) - Fiscal Standard
07/16/16 05:04 PMNovartis AG Stock Price Update Today (NVS) - July 16, 2016 - Money Morning
07/15/16 11:10 AMNovartis (NVS) Likely to Beat Q2 Earnings: Stock to Gain? -
07/15/16 10:27 AMNovartis AG Stock Price Update Today (NVS) - July 15, 2016 - Money Morning
07/15/16 10:07 AMWhat Is Ligand Pharmaceuticals’s Expected Revenue Growth in 2016? -
07/14/16 05:51 PMNovartis AG (NYSE:NVS) Earnings Concentration and Analyst Target Watch - Engelwood Daily
07/14/16 05:51 PMAnalyst Recommendations Review: Novartis AG (NYSE:NVS) - News Oracle
07/14/16 09:09 AMStock Wooing Investors After Increase: Novartis AG (NYSE:NVS) - Telanagana Press
07/14/16 09:09 AMBuy or Hold? What are Analysts Saying About Novartis AG (NYSE:NVS) - Telanagana Press
07/14/16 09:09 AMHC Stocks Indications: Pernix Therapeutics Holdings Inc (NASDAQ:PTX), Novartis AG (ADR) (NYSE:NVS) - share market updates (press release)
07/14/16 09:09 AMNovartis AG Stock Price Update Today (NVS) - July 14, 2016 - Money Morning
07/14/16 09:06 AMHow Can Celator’s Portfolio Complement Jazz Pharmaceuticals? -
07/13/16 05:56 PMCell Medica Acquires Delenex, Which Avoided A Novartis AG (NYSE:NVS) Takeover - Market Exclusive
07/13/16 08:29 AMCell Medica Acquires Delenex, Which Avoided A Novartis AG (NYSE:NVS) Takeover
07/13/16 02:22 AMAstraZeneca resolves Faslodex patent litigation in U.S. -
07/12/16 05:49 PMNovartis AG (NYSE:NVS) Copy Of Amgen, Inc. (NASDAQ:AMGN) Enbrel Hangs In the Balance Over Similarity Concerns
07/12/16 04:49 PMFDA Panel Resoundingly Backs Amgen's Biosimilar Humira -

Social

About Novartis AG

Novartis AG logoNovartis AG is a holding company that, through its subsidiaries, is engaged in development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals around the world. Its portfolio includes medicines, eye care, generic pharmaceuticals, preventive vaccines and over-the-counter (OTC) products. The Company's segments include Pharmaceuticals, which include patent-protected prescription medicines; Alcon, which include surgical, ophthalmic pharmaceutical and vision care products; Sandoz, which include generic pharmaceuticals, and Consumer Health, which includes the OTC Division. Pharmaceuticals products include Afinitor/Votubia, Exjade, Galvus, Exforge and Voltaren, among others. Its Sandoz products include Valsartan (Diovan), Cyclophosphamide injection and AirFluSal Forspiro, among others. Its OTC offers readily available consumer medicine. The Company operates Admune Therapeutics as a wholly owned subsidiary.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Major
  • Sub-Industry: N/A
  • Exchange: NYSE
  • Symbol: NVS
  • CUSIP:
Key Metrics:
  • Previous Close: $83.26
  • 50 Day Moving Average: $80.80
  • 200 Day Moving Average: $77.04
  • P/E Ratio: 29.73
  • P/E Growth: 2.85
  • Market Cap: $198.26B
  • Beta: 0.58
  • Current Year EPS Consensus Estimate: $4.76 EPS
  • Next Year EPS Consensus Estimate: $5.13 EPS
Additional Links:
Novartis AG (NYSE:NVS) Chart for Sunday, July, 31, 2016